Needham & Company Reiterates a 'Buy' on Alnylam Pharmaceuticals (ALNY); Accelerated ALN-TTR Development May Sustain Stock Momentum in 2012
ALNY Hot Sheet
Rating Summary:7 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 20 | Down: 11 | New: 38
Needham & Company reiterates a 'Buy' on Alnylam Pharmaceuticals (NASDAQ: ALNY) price target of $16.00.
Analyst, Alan Carr, said, "Alnylam management reviewed 4Q11 in a quarterly conference call yesterday after market close. With the January 2012 restructuring, the company is placing greater emphasis on development of ALN-TTR-02 (transthyretin amyloidosis) and ALN-APC (hemophilia). ALN-TTR-02 may be ready for a pivotal Phase 3 trial in 2013. ALN-APC is expected to enter the clinic in 1H13."
"The stock has done well over the course of 2H11 and into 2012, in concert with positive developments from the company pipeline. We continue to believe the stock is undervalued (~$300M EV). Recent ALN-PCS and ALN-TTR proof of concept data have broad positive implications for RNAi therapy as a whole."
For an analyst ratings summary and ratings history on Alnylam Pharmaceuticals click here. For more ratings news on Alnylam Pharmaceuticals click here.
Shares of Alnylam Pharmaceuticals closed at $13.05 yesterday, with a 52 week range of $5.88-$13.25.
Discover Wall Street's best ratings calls with the pros - Ratings Insider Elite. Free Trial!
Analyst, Alan Carr, said, "Alnylam management reviewed 4Q11 in a quarterly conference call yesterday after market close. With the January 2012 restructuring, the company is placing greater emphasis on development of ALN-TTR-02 (transthyretin amyloidosis) and ALN-APC (hemophilia). ALN-TTR-02 may be ready for a pivotal Phase 3 trial in 2013. ALN-APC is expected to enter the clinic in 1H13."
"The stock has done well over the course of 2H11 and into 2012, in concert with positive developments from the company pipeline. We continue to believe the stock is undervalued (~$300M EV). Recent ALN-PCS and ALN-TTR proof of concept data have broad positive implications for RNAi therapy as a whole."
For an analyst ratings summary and ratings history on Alnylam Pharmaceuticals click here. For more ratings news on Alnylam Pharmaceuticals click here.
Shares of Alnylam Pharmaceuticals closed at $13.05 yesterday, with a 52 week range of $5.88-$13.25.
Discover Wall Street's best ratings calls with the pros - Ratings Insider Elite. Free Trial!
You May Also Be Interested In
- Barclays Maintains an 'Equalweight' on J. C. Penney (JCP); Slashing PT on Disappointing Results
- UBS Raises Price Target and Estimates on PetSmart (PETM); Sees Sustained Sales and Margin Benefit
- UBS Maintains a 'Buy' on Ralph Lauren (RL); Taking A More Conservative Approach
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Needham & Company, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
